Synopsis
Synopsis
0
VMF
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Molecular Weight | 534.4 g/mol |
---|---|
Molecular Formula | C23H21F7N4O3 |
XLogP3 | 4.2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 6 |
Exact Mass | 534.15018768 g/mol |
Monoisotopic Mass | 534.15018768 g/mol |
Topological Polar Surface Area | 75.2 A^2 |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 810 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 3 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Aprepitant |
PubMed Health | Aprepitant (By mouth) |
Drug Classes | Antiemetic |
Drug Label | EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist, chemically described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one. Its empiric... |
Active Ingredient | Aprepitant |
Dosage Form | Capsule |
Route | Oral |
Strength | 125mg; 80mg; 40mg |
Market Status | Prescription |
Company | Sandoz |
2 of 4 | |
---|---|
Drug Name | Emend |
PubMed Health | Aprepitant (By mouth) |
Drug Classes | Antiemetic |
Drug Label | EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist, chemically described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one. Its empiric... |
Active Ingredient | Aprepitant; Fosaprepitant dimeglumine |
Dosage Form | Capsule; Powder |
Route | Intravenous; Oral |
Strength | eq 150mg base/vial; 125mg; 80mg; 40mg |
Market Status | Prescription |
Company | Merck; Merck And |
3 of 4 | |
---|---|
Drug Name | Aprepitant |
PubMed Health | Aprepitant (By mouth) |
Drug Classes | Antiemetic |
Drug Label | EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist, chemically described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one. Its empiric... |
Active Ingredient | Aprepitant |
Dosage Form | Capsule |
Route | Oral |
Strength | 125mg; 80mg; 40mg |
Market Status | Prescription |
Company | Sandoz |
4 of 4 | |
---|---|
Drug Name | Emend |
PubMed Health | Aprepitant (By mouth) |
Drug Classes | Antiemetic |
Drug Label | EMEND (aprepitant) is a substance P/neurokinin 1 (NK1) receptor antagonist, chemically described as 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one. Its empiric... |
Active Ingredient | Aprepitant; Fosaprepitant dimeglumine |
Dosage Form | Capsule; Powder |
Route | Intravenous; Oral |
Strength | eq 150mg base/vial; 125mg; 80mg; 40mg |
Market Status | Prescription |
Company | Merck; Merck And |
Tofigh Daru develops & synthesizes a diverse range of APIs in Anticancer, Narcotics, Cardiovascular to Immunomodulatory Segments.
GDUFA
DMF Review : Reviewed
Rev. Date : 2022-05-31
Pay. Date : 2022-05-16
DMF Number : 35497
Submission : 2022-04-26
Status : Active
Type : II
Certificate Number : CEP 2022-247 - Rev 00
Issue Date : 2024-10-29
Type : Chemical
Substance Number : 2757
Status : Valid
NDC Package Code : 64567-0021
Start Marketing Date : 2021-01-14
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
Octavius has been empowering lives since 1980 by providing quality products like DC granules, APIs and FDFs.
Pharmathen provides life cycle Management solutions for branded pharma, as well as to develop & establish new technology platforms.
GDUFA
DMF Review : Reviewed
Rev. Date : 2018-03-20
Pay. Date : 2017-11-15
DMF Number : 32203
Submission : 2017-12-06
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33266
Submission : 2019-03-07
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25715
Submission : 2012-01-17
Status : Inactive
Type : II
Certificate Number : R0-CEP 2019-025 - Rev 01
Issue Date : 2020-04-07
Type : Chemical
Substance Number : 2757
Status : Valid
Aprepitant, Micronised And Non Micronised
Certificate Number : CEP 2022-247 - Rev 00
Status : Valid
Issue Date : 2024-10-29
Type : Chemical
Substance Number : 2757
Certificate Number : CEP 2022-365 - Rev 00
Status : Valid
Issue Date : 2024-07-02
Type : Chemical
Substance Number : 2757
Certificate Number : CEP 2017-196 - Rev 02
Status : Valid
Issue Date : 2024-03-01
Type : Chemical
Substance Number : 2757
Certificate Number : CEP 2017-051 - Rev 01
Status : Valid
Issue Date : 2023-12-06
Type : Chemical
Substance Number : 2757
Certificate Number : CEP 2021-434 - Rev 01
Status : Valid
Issue Date : 2023-10-24
Type : Chemical
Substance Number : 2757
Certificate Number : CEP 2017-041 - Rev 03
Status : Valid
Issue Date : 2023-10-13
Type : Chemical
Substance Number : 2757
Certificate Number : CEP 2017-192 - Rev 03
Status : Valid
Issue Date : 2024-05-02
Type : Chemical
Substance Number : 2757
Certificate Number : CEP 2021-323 - Rev 00
Status : Valid
Issue Date : 2024-01-22
Type : Chemical
Substance Number : 2757
Certificate Number : R0-CEP 2019-025 - Rev 01
Status : Valid
Issue Date : 2020-04-07
Type : Chemical
Substance Number : 2757
Certificate Number : R0-CEP 2019-117 - Rev 00
Status : Valid
Issue Date : 2020-09-04
Type : Chemical
Substance Number : 2757
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Aprepitant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Aprepitant, including repackagers and relabelers. The FDA regulates Aprepitant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Aprepitant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Aprepitant manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Aprepitant supplier is an individual or a company that provides Aprepitant active pharmaceutical ingredient (API) or Aprepitant finished formulations upon request. The Aprepitant suppliers may include Aprepitant API manufacturers, exporters, distributors and traders.
click here to find a list of Aprepitant suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Aprepitant DMF (Drug Master File) is a document detailing the whole manufacturing process of Aprepitant active pharmaceutical ingredient (API) in detail. Different forms of Aprepitant DMFs exist exist since differing nations have different regulations, such as Aprepitant USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Aprepitant DMF submitted to regulatory agencies in the US is known as a USDMF. Aprepitant USDMF includes data on Aprepitant's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Aprepitant USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Aprepitant suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Aprepitant Drug Master File in Japan (Aprepitant JDMF) empowers Aprepitant API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Aprepitant JDMF during the approval evaluation for pharmaceutical products. At the time of Aprepitant JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Aprepitant suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Aprepitant Drug Master File in Korea (Aprepitant KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Aprepitant. The MFDS reviews the Aprepitant KDMF as part of the drug registration process and uses the information provided in the Aprepitant KDMF to evaluate the safety and efficacy of the drug.
After submitting a Aprepitant KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Aprepitant API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Aprepitant suppliers with KDMF on PharmaCompass.
A Aprepitant CEP of the European Pharmacopoeia monograph is often referred to as a Aprepitant Certificate of Suitability (COS). The purpose of a Aprepitant CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Aprepitant EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Aprepitant to their clients by showing that a Aprepitant CEP has been issued for it. The manufacturer submits a Aprepitant CEP (COS) as part of the market authorization procedure, and it takes on the role of a Aprepitant CEP holder for the record. Additionally, the data presented in the Aprepitant CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Aprepitant DMF.
A Aprepitant CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Aprepitant CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Aprepitant suppliers with CEP (COS) on PharmaCompass.
A Aprepitant written confirmation (Aprepitant WC) is an official document issued by a regulatory agency to a Aprepitant manufacturer, verifying that the manufacturing facility of a Aprepitant active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Aprepitant APIs or Aprepitant finished pharmaceutical products to another nation, regulatory agencies frequently require a Aprepitant WC (written confirmation) as part of the regulatory process.
click here to find a list of Aprepitant suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Aprepitant as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Aprepitant API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Aprepitant as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Aprepitant and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Aprepitant NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Aprepitant suppliers with NDC on PharmaCompass.
Aprepitant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Aprepitant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Aprepitant GMP manufacturer or Aprepitant GMP API supplier for your needs.
A Aprepitant CoA (Certificate of Analysis) is a formal document that attests to Aprepitant's compliance with Aprepitant specifications and serves as a tool for batch-level quality control.
Aprepitant CoA mostly includes findings from lab analyses of a specific batch. For each Aprepitant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Aprepitant may be tested according to a variety of international standards, such as European Pharmacopoeia (Aprepitant EP), Aprepitant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Aprepitant USP).
LOOKING FOR A SUPPLIER?